Karyopharm Therapeutics Highlights Selinexor Pipeline Progress and Myelofibrosis Opportunity in New Corporate Presentation
Karyopharm Therapeutics Inc. has released a corporate presentation detailing the progress of its selinexor pipeline for cancer treatments, including myelofibrosis, multiple myeloma, and endometrial cancer. Selinexor is approved in 50 countries, with a potential $1 billion annual revenue for myelofibrosis. Phase 3 trial results are expected in 2026. The company reports strong commercial performance and a cash runway into Q2 2026.
Karyopharm Therapeutics Inc. has published a corporate presentation highlighting ongoing clinical development programs and commercial progress. The presentation outlines the company’s focus on advancing selinexor (XPOVIO®/NEXPOVIO®) for multiple cancer indications, including myelofibrosis, multiple myeloma, and endometrial cancer. Selinexor is now approved in 50 countries, with a peak annual revenue opportunity for myelofibrosis estimated at up to $1 billion, pending positive data and regulatory approval. Top-line results from the Phase 3 SENTRY trial in myelofibrosis are expected in March 2026, with additional Phase 3 data in endometrial cancer anticipated mid-2026. The company also reports a strong commercial performance in its multiple myeloma franchise and a cash runway extended into the second quarter of 2026. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
